A phase I study to evaluate the tolerance, safety, pharmacokinetic characteristics and preliminary efficacy of PM8001 in patients with advanced solid tumors and a phase IIa study to investigate the efficacy of PM8001 in patients with advanced solid tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 09 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PM 8001 (Primary)
Indications Cervical cancer; Cholangiocarcinoma; Liver cancer; Liver metastases; Non-small cell lung cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use

Most Recent Events

07 Jun 2022 Results (n=108; 16 Dec 2021) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
03 Dec 2021 Results published in the Biotheus Media Release.
03 Dec 2021 According to a Biotheus media release, this study was approved by the Chinese NMPA in March 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight